AstraZeneca: positive results for prostate cancer
(CercleFinance.com) - Positive high-level results from the CAPItello-281 trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) compared to abiraterone and ADT with placebo in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
The Truqap combination showed an early trend towards improved OS compared with abiraterone and ADT with placebo, the company says. The trial will continue as planned to further evaluate OS as a key secondary endpoint.
Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death in men worldwide.
Newly diagnosed mHSPC is an aggressive form of the disease associated with poor outcomes. Approximately 200,000 patients are diagnosed with mHSPC each year.
The trial's principal investigator said that patients with this aggressive form of PTEN-deficient prostate cancer currently face a particularly poor prognosis, and there is an urgent need for new treatments that improve on current therapies. The results observed with capivasertib in combination with abiraterone-prednisone and androgen deprivation therapy in the CAPItello-281 trial represent a step forward for these patients.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The Truqap combination showed an early trend towards improved OS compared with abiraterone and ADT with placebo, the company says. The trial will continue as planned to further evaluate OS as a key secondary endpoint.
Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death in men worldwide.
Newly diagnosed mHSPC is an aggressive form of the disease associated with poor outcomes. Approximately 200,000 patients are diagnosed with mHSPC each year.
The trial's principal investigator said that patients with this aggressive form of PTEN-deficient prostate cancer currently face a particularly poor prognosis, and there is an urgent need for new treatments that improve on current therapies. The results observed with capivasertib in combination with abiraterone-prednisone and androgen deprivation therapy in the CAPItello-281 trial represent a step forward for these patients.
Copyright (c) 2024 CercleFinance.com. All rights reserved.